Global Neurology Academy
The Global Neurology Academy (GNA) series offers certified education modules and video interviews from leading MS experts from across the globe as they address topics such as induction therapy in relapsing-remitting multiple sclerosis; No Evidence of Disease Activity (NEDA) concept; how different agents used in MS management may be utilized in induction therapy; appreciation of how reductions in end-organ damage impact patient quality-of-life; mechanisms of action of the classical as well as emergent agents; key issues associated with making the correct differential diagnosis of multiple sclerosis, in addition to how best to incorporate prognostic indicators into clinical decision-making; current and emergent novel oral agents in MS management; and diagnostic strategies and identifying predictors of outcome.
For more information about GNA, visit www.globalneurologyacademy.org.
181-195 of 232
Understanding Schizophrenia: New Insights on Prevalence, Treatment, and Quality of Life
NeuroFrontiersUnderstanding Schizophrenia: New Insights on Prevalence, Treatment, and Quality of Life
Gaps in Schizophrenia Spectrum Disorders Care: A Look at Causes and Solutions
NeuroFrontiersGaps in Schizophrenia Spectrum Disorders Care: A Look at Causes and Solutions
Managing MS-Related Fatigue with Therapeutic, Lifestyle, and Behavioral Interventions
On the Frontlines of Multiple SclerosisManaging MS-Related Fatigue with Therapeutic, Lifestyle, and Behavioral Interventions
Fatigue in Multiple Sclerosis: Investigating Longitudinal Determinants
NeuroFrontiersFatigue in Multiple Sclerosis: Investigating Longitudinal Determinants
Developments in Duchenne Muscular Dystrophy Care: Examining the Options
NeuroFrontiersDevelopments in Duchenne Muscular Dystrophy Care: Examining the Options
Schizophrenia Care: Managing Symptoms with Muscarinic Receptor Agonists
On the Frontlines of SchizophreniaSchizophrenia Care: Managing Symptoms with Muscarinic Receptor Agonists
- advertisement
Developments in Schizophrenia Care: An Alternative to Dopamine Receptor Blockage
NeuroFrontiersDevelopments in Schizophrenia Care: An Alternative to Dopamine Receptor Blockage
Differentiating gMG for Diagnostic Precision: The Role of Fatigable Weakness
NeuroFrontiersDifferentiating gMG for Diagnostic Precision: The Role of Fatigable Weakness
Schizophrenia Care: Improving Social Cognition and Motivation
On the Frontlines of SchizophreniaSchizophrenia Care: Improving Social Cognition and Motivation
Examining Schizophrenia Risk: The Influence of B12 Levels in Early Pregnancy
NeuroFrontiersExamining Schizophrenia Risk: The Influence of B12 Levels in Early Pregnancy
Unseen Struggles: Impacts of Homelessness on Women with Schizophrenia
NeuroFrontiersUnseen Struggles: Impacts of Homelessness on Women with Schizophrenia
- advertisement
NKX019: A Potential New Frontier in Generalized Myasthenia Gravis Therapy
NeuroFrontiersNKX019: A Potential New Frontier in Generalized Myasthenia Gravis Therapy
Beyond Amyloid and Tau: A Multimarker Approach to Alzheimer's Detection
NeuroFrontiersBeyond Amyloid and Tau: A Multimarker Approach to Alzheimer's Detection
Debunking Misconceptions Regarding the Revised Alzheimer’s Diagnostic Criteria
NeuroFrontiersDebunking Misconceptions Regarding the Revised Alzheimer’s Diagnostic Criteria









































